LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK)…
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company’s internal research and preclinical development programmes, focused on degenerative…
Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes, is pleased to announce the following appointments: Dr Frank M Armstrong…
By Gareth Mackie, The Scotsman A university spin-out that specialises in potential treatments for type 2 diabetes has bolstered its boardroom in the wake of a £4.5 million cash injection. Glasgow-based Caldan Therapeutics, a spin-out from the universities of Glasgow and Southern Denmark, has appointed…
Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser…
Hamburg, Germany, 22 March 2016 – Topas Therapeutics GmbH (“Topas”), a Hamburg/Germany based company, today announced the closing of its Series A financing round. This investment provides the company with EUR 14 million (USD 15.75 million). The round was led by Epidarex Capital and includes…
Edinburgh, United Kingdom, 9th March, 2016 – Edinburgh Molecular imaging Ltd (EM Imaging) announced today that the company has received a SBRI Stratified Medicine Connecting the UK Infrastructure Phase I grant from the UK’s innovation agency, Innovate UK. The SBRI grant aims to accelerate and increase…
Louisville, Ky., Feb. 12, 2016 – Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB…
By Varun Saxena, FierceMedicalDevices December 10, 2015 – Harpoon Medical Executive Vice President Peter Boyd told FierceMedicalDevices that cardiology titan Edwards Lifesciences acquired an option to purchase the startup so that it can someday offer a solution for both functional and degenerative mitral valve disease…
By Varun Saxena, FierceMedicalDevices December 9, 2015 – Just as the flurry of M&A activity in the transcatheter mitral valve repair arena appears to be dying down, with nearly all of the developers snapped up by industry bigwigs, TAVR pioneer Edwards Lifesciences is threatening to…